Media Release

All Categories

10 March 2016

Thinking beyond the ideas boom: What Australia really needs is later stage capital and experience

17 December 2015

OneVentures’ Innovation and Growth Fund II hits $100 million in FUM

15 December 2015

OneVentures commits $3M to launch Australian wearable technology innovation for global dementia market

26 March 2015

Hatchtech Pty Ltd to explore strategic alternatives for commercialization of Xeglyze™ lotion in the U.S.

21 October 2014

Hatchtech announces successful results from Phase 2 ovicidal study

26 August 2014

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

Awards, Media Release

24 March 2014

charmhealth names Gary Lakin as new CEO

29 January 2014

Scale Investment in Paloma

12 December 2013

Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

31 October 2013

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

25 September 2013

charmhealth appoints Health-IT Expert to the Board

02 May 2013

NICTA’s ‘Incoming’ mobile video start-up company switches on with $1.1M in seed financing

11 April 2013

OneVentures team ‘charmed’ by Queensland Health-IT company

12 March 2013

Hugh Alsop appointed Hatchtech CEO

27 November 2012

Hatchtech publish data on Head Lice treatment safety study and mechanism of action

08 October 2012

Vaxxas Appoints David Hoey as Company’s First CEO

08 October 2012

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

03 September 2012

Hatchtech announce successful End-of-Phase 2 for head lice product DeOvo™

17 April 2012

Best Venture Capital Investment at the 2012 Vaccine Industry Excellence Awards

Awards, Media Release

26 October 2010

Hatchtech raises $6.3m for DeOvo™ Head Lice Phase 2b Clinical Trial

decor decor decor
decor decor decor decor decor